Biotech Values

[dewophile]

mygn

BRACAnalysis accounted for $82.5M which is nearly 88% of total revenues ($93.9M) for the 4Q10

to have so much of one's revenue dependent on one product is definitely a concern. on the flip side if they can get some traction from some of the other products there is quite a bit of upside

Ps: i'm surprised colaris isn't selling more - the company has stated its the fastest growing product, and i know some gyns who never heard of it and are now starting to order the test..we'll see